JAZZ vs. PRGO, CORT, ELAN, CYTK, APLS, VKTX, CERE, IONS, ITCI, and ASND
Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Perrigo (PRGO), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), Cerevel Therapeutics (CERE), Ionis Pharmaceuticals (IONS), Intra-Cellular Therapies (ITCI), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Jazz Pharmaceuticals presently has a consensus price target of $195.08, suggesting a potential upside of 78.22%. Perrigo has a consensus price target of $40.67, suggesting a potential upside of 27.32%. Given Jazz Pharmaceuticals' higher possible upside, equities research analysts plainly believe Jazz Pharmaceuticals is more favorable than Perrigo.
Jazz Pharmaceuticals received 331 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 80.49% of users gave Jazz Pharmaceuticals an outperform vote while only 66.78% of users gave Perrigo an outperform vote.
Jazz Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Perrigo had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 11 mentions for Perrigo and 9 mentions for Jazz Pharmaceuticals. Perrigo's average media sentiment score of 0.80 beat Jazz Pharmaceuticals' score of 0.70 indicating that Perrigo is being referred to more favorably in the news media.
89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 4.4% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Jazz Pharmaceuticals has a net margin of 10.82% compared to Perrigo's net margin of -0.27%. Jazz Pharmaceuticals' return on equity of 31.27% beat Perrigo's return on equity.
Jazz Pharmaceuticals has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.
Summary
Jazz Pharmaceuticals beats Perrigo on 12 of the 18 factors compared between the two stocks.
Get Jazz Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jazz Pharmaceuticals Competitors List
Related Companies and Tools
